已发表论文

塞来昔布通过抑制 SDF1 诱导的 CXCR4 内吞作用来遏制皮肤鳞状细胞癌细胞迁移

 

Authors Gong T, Yu Y, Yang B, Lin M, Huang JW, Cheng B, Ji C

Received 17 July 2018

Accepted for publication 15 October 2018

Published 12 November 2018 Volume 2018:11 Pages 8063—8071

DOI https://doi.org/10.2147/OTT.S180472

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Background: Cutaneous squamous cell carcinoma (CSCC), the main type of non-melanoma skin cancer (NMSC), contributes to 20-30% of the overall number of NMSC cases. Some CSCCs are observed to have metastatic potential induced by solar ultra violet (UV) radiation. Celecoxib, a nonsteroidal anti-inflammatory drug, has been largely associated with prevention of many cancer types. However, the relationship between celecoxib and CSCC cell migration has yet to be determined.
Methods: To determine the association between celecoxib and CSCC, we performed a series of studies in human samples and in vitro models to assess the influence of celecoxib in CSCC cell migration. 
Results: In the present study, we found that celecoxib suppresses CSCC cell migration via inhibition of SDF1-induced endocytosis of CXCR4. In addition, ERK/AKT signaling pathways were found to play a key role in this biological process.
Conclusion: Our study provides promising evidence that celecoxib could serve as a potential preventative agent for the metastasis of CSCC cells.
Keywords: celecoxib, SDF1, cell migration, CXCR4, ERK–Akt pathway




Figure 3 Celecoxib repressed SDF1-induced endocytosis of...